Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[31] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet-Loiseau, Herve
Fonseca, Rafael
Siegel, David
Dimopoulos, Meletios A.
Spicka, Ivan
Masszi, Tamas
Hajek, Roman
Rosinol, Laura
Goranova-Marinova, Vesselina
Mihaylov, Georgi
Maisnar, Vladimir
Mateos, Maria-Victoria
Wang, Michael
Niesvizky, Ruben
Oriol, Albert
Jakubowiak, Andrzej
Minarik, Jiri
Palumbo, Antonio
Bensinger, William
Kukreti, Vishal
Ben-Yehuda, Dina
Stewart, A. Keith
Obreja, Mihaela
Moreau, Philippe
BLOOD, 2016, 128 (09) : 1174 - 1180
[32] Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)
Cavo, Michele
Pantani, Lucia
Patriarca, Francesca
Petrucci, Maria Teresa
Galli, Monica
Di Raimondo, Francesco
Rossi, Giuseppe
Palumbo, Antonio
Tacchetti, Paola
Offidani, Massimo
Montefusco, Vittorio
Narni, Franco
Spadano, Tonino
Cellini, Claudia
Pescosta, Norbert
Baldini, Luca
Ledda, Antonio
Di Toritto, Tommaso Caravita
Pezzi, Annalisa
Falcone, Antonietta
Nozzoli, Chiara
Zambello, Renato
Masini, Luciano
Gherlinzoni, Filippo
Petti, Maria Concetta
Derudas, Daniele
Ballanti, Stelvio
De Stefano, Valerio
Baccarani, Michele
BLOOD, 2011, 118 (21) : 816 - 816
[33] Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Avet-Loiseau, Herve
Ludwig, Heinz
Landgren, Ola
Paiva, Bruno
Morris, Chris
Yang, Hui
Zhou, Kefei
Ro, Sunhee
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01): : E30 - E37
[34] Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients
Yoshizawa, Seiichiro
Umezu, Tomohiro
Ohyashiki, Junko H.
Iida, Shinsuke
Ohyashiki, Kazuma
BLOOD, 2013, 122 (21)
[35] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
Jennifer L. J. Heaney
John P. Campbell
Gulnaz Iqbal
David Cairns
Alex Richter
J. Anthony Child
Walter Gregory
Graham Jackson
Martin Kaiser
Roger Owen
Faith Davies
Gareth Morgan
Janet Dunn
Mark T. Drayson
Leukemia, 2018, 32 : 1727 - 1738
[36] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
Heaney, Jennifer L. J.
Campbell, John P.
Iqbal, Gulnaz
Cairns, David
Richter, Alex
Child, J. Anthony
Gregory, Walter
Jackson, Graham
Kaiser, Martin
Owen, Roger
Davies, Faith
Morgan, Gareth
Dunn, Janet
Drayson, Mark T.
LEUKEMIA, 2018, 32 (08) : 1727 - 1738
[37] Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma
Ghosh, Nilanjan
Ye, Xiaobu
Ferguson, Anna
Huff, Carol Ann
Borrello, Ivan
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 593 - 599
[38] Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
Ghosh, Nilanjan
Ferguson, Anna
Ye, Xiaobu
Huff, Carol A.
Borrello, Ivan M.
BLOOD, 2009, 114 (22) : 1119 - 1119
[39] CARFILZOMIB AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL AND RESPONSE RATES VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM): THE PHASE 3 STUDY ENDEAVOR
Dimopoulos, M.
Moreau, P.
Palumbo, A.
Joshua, D.
Pour, L.
Hajek, R.
Facon, T.
Ludwig, H.
Oriol, A.
Goldschmidt, H.
Rosinol, L.
Straub, J.
Suvorov, A.
Araujo, C.
Rimashevskaya, E.
Pika, T.
Gaidano, G.
Weisel, K.
Goranova-Marinova, V.
Schwarer, A.
Minuk, L.
Masszi, T.
Karamanesht, I.
Offidani, M.
Hungria, V.
Spencer, A.
Gillenwater, H.
Mohamed, N.
Feng, S.
Chng, W. J.
HAEMATOLOGICA, 2015, 100 : 336 - 336
[40] Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival
Merz, Almuth M. A.
Merz, Maximilian
Zhang, Yali
Stecklein, Kathryn
Pleskow, Jordan
Chen, George L.
Buck, Dennis A.
Mohammadpour, Hemn
Herr, Megan M.
Elshoury, Amro
Hillengass, Jens
McCarthy, Philip L.
Hahn, Theresa
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 245.e1 - 245.e8

← 1 2 3 4 5 →